Phosphohistone H3 (PHH3) is a marker specific for cells undergoing mitosis. Serine 10 of Histone H3 is phosphorylated in association with mitotic chromatin condensation in late G2 and M phase of the cell cycle and thus, PHH3 can distinguish mitosis from apoptotic nuclei. The range of percentage PHH3 positive tumor nuclei was from 0.0 to 6.6% (median value 0.8%). Increased expression of PHH3 was significantly associated with tumor thickness (p = 0.031), presence of tumor ulceration (p =0.041) and tumor necrosis (p = 0.027), but not with Clark's level of invasion. High levels of PHH3 was associated with increased mitotic count (p = 0.003) and high Ki-67 expression (p = 0.002). For central nervous system tumors, melanoma, soft tissue tumors, GIST, etc., PHH3 mAb is helpful for tumor pathological classification and prognosis.
Specifications
Catalog No.
BX50087
Clone No.
BP6092
Application
IHC-P
Subcellular location
Nucleus
Control
Tonsil Tissue
Recommended method
HIER
Volume
100μl/vial, 1ml/vial
Dilution
1:100-1:200
Immunogen
Synthetic peptide corresponding to Phosphohistone H3 (PHH3) residues within aa1-100 (phospho S10) was used as an immunogen.
Reference
1.Thareja S, et al. Am J Dermatopathol. 2014 Jan; 36(1):64-7.
2.Casper DJ, et al. Am J Dermatopathol. 2010 Oct; 32(7):650-4.